We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Phadia Chooses Aushon’s Microarray Technology to Accelerate Diagnostic Allergen and Autoimmunity Assay Development

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Aushon BioSystems, Inc. announces that Phadia will utilize the Aushon 2470 Arrayer technology in its Multiplexing Diagnostics GmbH division. The 2470 will enable Phadia to advance its research efforts focusing on the characterization of new allergens, and the discovery of patterns in molecular diagnosis for allergy and autoimmunity.

“In many areas, antigens are very different and require specific buffers or additives,” said Dr Christian Harwanegg, Chief Operating Officer for Phadia Multiplexing Diagnostics. “That requires a very robust and reliable printing technology, which the 2470 provides. We also needed to focus on our application and assay content optimization, and not just on our manufacturing processes. By integrating the 2470 into our process stream, we’ll be able to optimize our output, while realizing better print quality – including CV's and grid precision – and far lower operating costs than with our previous printing technology."

The Aushon 2470 Arrayer has been installed in leading institutions throughout North America, Europe and Asia to provide high-density microarray printing for both genomic and proteomic applications such as reverse phase arrays and multiplex diagnostics. It is able to print virtually any sample – including cell lysates and blood – onto substrates with unique shapes and chemistries, as well as the most delicate of substrates such as nitrocellulose and silicon chips.